Peg-Interferon alpha-2b
Phase 3Small molecule
Merck & Co.Peg-Interferon alpha-2b is one of 45 small molecule programs targeting Fibroma. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
306 competitors in Hepatitis C
#DrugCompanyPhaseTrials
1Daklinza
Bristol-Myers SquibbPhase 3
Zepatier
Merck & Co.Phase 3
Peginterferon Alfa-2
RochePhase 3
Lexapro
AbbViePhase 3
Pegylated Interferon
Merck & Co.Phase 3
Gocovri
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
Zetia
OOrganon and Co
Phase 3
Thymalfasin
SSciClone Pharmaceuticals
Phase 3
Pegylated Interferon Lambda
Bristol-Myers SquibbPhase 3
PEG-IFN Alfa-2a
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Peg-Interferon alpha-2b. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company